Daniel Lang, a partner in Goodwin’s Technology and Life Sciences group and co-chair of the firm’s Technology practice in New York. He has extensive experience advising high-growth technology and life sciences companies and investors that focus on these companies. His practice spans the corporate lifecycle, covering start-up formations, seed, venture capital and growth equity financings, joint ventures and other strategic transactions, mergers and acquisitions (M&A), and IPOs, PIPEs and other capital markets transactions. Daniel also regularly advises clients on corporate governance, securities laws compliance and other external “general counsel” matters.
Experience
Daniel represents companies and investors in the technology and life sciences sectors, including e-commerce, consumer products, beauty and fashion, sports, media and entertainment, consumer and enterprise software, AI, cybersecurity, deep tech, adtech, fintech, insurtech, real estate tech, medtech, digital health, wellness, healthcare and biotechnology.
Representative clients include private companies: Bem!, BetMGM, Biteable, Carebridge, Chord Commerce, Coderbyte, Enlaye, Glossier, Hibercell, Hoth Intelligence, Instant Teams, JLo Beauty, KaloCyte, Main Street Rural, Nirvana, Novakid, Paperless Post, Prevu, Revivn, Sakara, Thrive Global, Tradewell Technologies, and Wave Sports + Entertainment; and investment funds: Ally Bridge Group, Alpha Wave Global, B Capital, Eden Global Partners, Glasswing Ventures, Norrsken VC, Nyca Partners, Perceptive Advisors, Qiming Venture Partners, RA Capital, Vivo Capital and Walter Ventures.
Representative Matters
- TRC 2004 in its acquisition by Candid Therapeutics
- Avvir in its acquisition by Hexagon AB
- Pyramid Biosciences in its acquisition by Biohaven
- Pond5 in its acquisition by Shutterstock
- Tara Biosystems in its acquisition by Valo Health
- Celtra in its acquisition by Symphony Technology Group
- Talla in its acquisition by Seva
- StreetLinx in its acquisition by Symphony
- Citus Health in its acquisition by Brightree, a subsidiary of ResMed
- arfa in its acquisition of Yaguara
- Hibercell in its acquisition of Biothera Pharmaceuticals’ Imprime PGG program
- Thrive Global in its acquisition of ZP Group and partnership with Walmart
- Thrive Global in its acquisition of Boundless Mind
- Syntimmune in its acquisition by Alexion Pharmaceuticals
- Aspire Health in its acquisition by Anthem
- Orchard Platform in its acquisition by Kabbage
- Glossier in its acquisition of Dynamo E-Media
- Thar Pharmaceuticals in its acquisition by Grünenthal
- Songza in its acquisition by Google
- M5 Networks in its acquisition by ShorTel
- XGraph in its acquisition by Add This (formerly Clearspring)
- Fidelis Security Systems in its acquisition by General Dynamics
- Nomi Technologies in its acquisition by Brickstream
- Tagman in its acquisition by Ensighten
- EveryScreen Media in its acquisition by Media6Degrees
- Fairhaven Capital in the acquisition of its portfolio company, CrowdTwist, by Oracle
- Glossier in various financings with participation by Lone Pine Capital, Institutional Venture Partners, Thrive Capital, Forerunner Ventures and Index Ventures
- Thrive Global in various financings with participation by Kleiner Perkins, Owl Ventures, JAZZ Venture Partners, IVP, Marc Benioff, Ray Dalio and Kevin Durant
- Chord Commerce in its financing by Eclipse Ventures and Foundation Capital
- Instant Teams in its financing led by Tiger Global and Squadra
- Nirvana in various financings from Northzone, Inspired Capital, Eniac Ventures and Surface Ventures
- Avvir in various financings with participation from Trust Ventures, Khosla Ventures, MetaProp and Stacked Capital
- Biteable in its Series A financing led by Cloud Apps Capital Partners
- Prevu in its financing led by Alpaca
- Celtra in various financings with participation by WPP, Unilever, Grandbanks Capital and Fairhaven Capital
- Digital Power Optimization Partners in its financing led by NYDIG
- Orchard Platform in its financing led by Thrive Capital, Spark Capital and Canaan Partners
- Hubble Contacts in various financings with participation by First Mark, Two River, Wildcat Capital Management, Founders Fund, Greycroft and Colgate
- Aircall in various financings with participation by Draper Esprit, Next World Capital, Balderton Capital and eFounders
- Linkwell Health in various financings with participation by HLM Venture Partners and Spark Capital
- Even Financial in its financing led by Canaan Partners and Lerer Hippeau Ventures
- Pond5 in its financing by Accel Partners and Stripes Group
- Paperless Post in various financings with participation by August Capital, Sherpalo Ventures, RRE Ventures, Mousse Partners and Top Tier
- arfa in its financings by Forerunner, Index, White Star Capital, Thrive, Box Group and others
- Megaphone TV in its financing led by Softbank Korea
- Glasswing Ventures in various investments, including Plannuh, Narrative, Talla, ZyloTech, Inrupt, ChaosSearch, askfora, Verusen, Elios, Narrative I/O, Labviva and Krane
- Perceptive Advisors in various investments, including Dynacure, Athira Pharma, Kindbody, Freenome and AavantiBio
- B Capital in various investments, including Lively, Hotspot Therapeutics, OncoMyx, Triumvira Immunologics, Nalu, Sift, Volastra and Atomwise
- Ally Bridge Group in various investments, including Profound Bio and Alumis
- Alpha Wave Global in various investments, including Attralus, Biolinq and Moonwalk
- Codiak BioSciences in its $83 million IPO and $66 million follow-on offering
- Foundation Medicine in its (i) $120 million IPO, (ii) collaboration and equity transaction with Roche, with total value in excess of $1 billion and (iii) sale of the remaining minority interest to Roche for $2.4 billion
- Ocera Therapeutics in its (i) acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration, (ii) $28 million PIPE financing, (iii) $25 million public offering and (iv) $25 million “at the market” offering facility
- Allena Pharmaceuticals in its $75 million IPO
- Chiasma in its (i) $102 million IPO, (ii) $34.5 million follow-on offering, (iii) $55 million follow-on offering, (iv) $70 million follow-on offering and (v) acquisition by Amryt
- The underwriters in (i) the $184 million IPO, (ii) a $116 million follow-on offering, (iii) a $230 million follow-on offering, (iv) a $200 million “at the market” offering facility and (v) a $200 million convertible note offering of Intrexon
- Vivo Capital in investments in ASLAN Pharmaceuticals, BioPharmX, Strongbridge Pharma, Kadmon, MEI Pharma, Sierra Oncology, Selecta BioSciences, Unicycive, Delcath and Gracell
- RA Capital as lead investor in $240 million PIPE financing of Cidara
- Intralinks, Tranzyme and Tengion in their IPOs
Areas of Practice
Professional Activities
Daniel is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech, Food-X and eLab NYC on venture financings and other elements of start-up law.
Credentials
Education
JD
Benjamin N. Cardozo School of Law
BA
Tufts University
Admissions
Bars
- New York
- New Jersey
Recognition & Awards
Daniel was named a New York Metro Rising Star by Super Lawyers. In law school, Daniel was an articles editor of the Cardozo Law Review.